Novartis announces positive new phase III brolucizumab (RTH258) data
Novartis announced a new data analysis showing that retinal fluid was detected less often in patients treated with brolucizumab (RTH258) 6 mg versus aflibercept over four visits between weeks 36 to 48. Retinal fluid is a key marker of disease activity in nAMD. September 22, 2018